Re: Medicinal Mismanagement, Peter Thurley, Aug. 25.
In response to Peter Thurley’s piece on Canada’s new medical cannabis access regulations and Canopy Growth Corp., I wanted to offer some perspective.
As the company’s CEO, I want to emphasize the benefit we have brought to all patients in Canada. As a public company operating multiple legal facilities and brands, we have enabled access through credible educational platforms for the medical community and offering legally approved, tested and safe products. This has made a major difference for all patients. The proof of this is in the numbers. After 13 years of grow-at-home regulations, about 35,000 Canadians accessed medical cannabis. Today, after only three years of a regulated approach almost 80,000 are legally medicating with cannabis.
We have established medical outreach and medical trial programs, engaged the insurance industry to increase coverage options, compelled the federal government to consider removing sales tax from medical cannabis, and developed accredited continuing education for physicians to give them the confidence to prescribe cannabis to patients. It is through this work, focusing on the barriers that separate cannabis from traditional therapeutic options, companies like Canopy Growth are paving the way for mainstream acceptance.
We are very much in favour of patient’s rights to grow their own supply and will support them in more ways than one. These range from the potential sale of seeds to the Home Grow Without Your Home program Thurley took exception to. We will also continue providing cannabis to people who value the peace of mind of having it produced to world-class standards and delivered to their doors.
Access is about options for safe supply at a cost-effective price point – we are all for that.